Company
Headquarters: Velizy-Villacoublay, France
Employees: 139
CEO: Mr. Stephane Piat
€6.4 Million
EUR as of Jan. 1, 2026
US$7.5 Million
| Company | Market Cap (USD) |
|---|---|
| Abbott | $216.15 B |
| Boston Scientific Corporation | $140.40 B |
| Stryker | $133.15 B |
| Medtronic | $123.20 B |
| Edwards Lifesciences Corporation | $50.10 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. It also develops orthotopic, bioprosthetic, self-regulating, pulsatile, and implantable systems, as well as power supply systems. The company was founded in 2008 and is based in Vélizy-Villacoublay, France.
Carmat SA has the following listings and related stock indices.
Stock: Euronext: ALCAR wb_incandescent
Stock: FSX: CXT wb_incandescent